Skip to main content

4 Result(s)

within Itzhak Katzir Remove this filter

and

  1. Article

    Open Access

    Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective

    To evaluate the association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and breast cancer (BC) risk.

    Nava Siegelmann-Danieli, Itzhak Katzir… in Breast Cancer Research and Treatment (2018)

    Download PDF (549 KB) View Article

  2. Article

    Open Access

    Trends in annual drug expenditure – a 16 year perspective of a public healthcare maintenance organization

    Modern drug therapy accounts for a major share of health expenditure and challenges public provider resources. The objective of our study was to compare drug expenditure trends for ten major drug classes over ...

    Yossef Lomnicky, Daniel Kurnik, Ronen Loebstein… in Israel Journal of Health Policy Research (2016)

    Download PDF (946 KB) View Article

  3. No Access

    Article

    Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen

    Endoxifen, the most active metabolite of the prodrug tamoxifen, is produced by cytochrome P450 CYP2D6. Breast cancer patients treated with tamoxifen who have reduced CYP2D6 activity, related to either genetic ...

    Nava Siegelmann-Danieli, Daniel Kurnik… in Breast Cancer Research and Treatment (2011)

  4. No Access

    Article

    A quantitative bioassay for nerve growth factor, using PC12 clones expressing different levels of trkA receptors

    Nerve growth factor (NGF) is a neurotrophin required for differentiation, development, and survival of the sympathetic nervous system, with many of its biological effects being mediated via trkA receptors. The...

    Itzhak Katzir, Jashovam Shani, Keren Regev… in Journal of Molecular Neuroscience (2002)